This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals (AGIO) Down 4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock
by Zacks Equity Research
Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 3.55% and 8.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Rides on Tibsovo Approval Amid Reliance on Celgene
by Zacks Equity Research
Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.
Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) names Dr. Jacqualyn Fouse as its next chief executive officer from Feb 1, 2019 onward.
Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates
by Zacks Equity Research
Agios (AGIO) incurs narrower-than-expected loss in Q2. Additionally, higher license and collaboration/milestone fees lead to a significant year-over-year rise in revenues.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 26.54% and 234.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Agios (AGIO) Q2 Loss Narrows, Revenue Beat Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reports narrower-than-expected loss in Q2. Higher license and collaboration milestone fees result in significant increase in year-over-year revenues.
What's in the Cards for Agios (AGIO) Stock in Q2 Earnings?
by Zacks Equity Research
On Agios' (AGIO) second-quarter 2018 conference call, investor focus is likely to be on the launch preparations of the company's newly FDA approved leukemia drug, Tibsovo.
Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug
by Zacks Equity Research
The biotech sector is in focus as bigwig Biogen gains on better-than-expected Q2 results. Others like Gilead, Amgen and Celgene too are slated to report shortly.
Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo
by Zacks Equity Research
Agios (AGIO) gains an FDA approval for its lead pipeline candidate, Tibsovo, for the treatment of relapsed/refractory acute myeloid leukemia (AML) in patients with an IDH1 mutation.
Agios Out-Licenses China Rights to Leukemia Drug Tibsovo
by Zacks Equity Research
Agios (AGIO) and CStone Pharmaceticals sign an exclusive collaboration and license agreement for the development and commercialization of its lead pipeline candidate Tibsovo.
Agios Pharmaceuticals (AGIO) Up 13.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios (AGIO) Progressing Well on Pipeline Amid Competition
by Zacks Equity Research
Agios (AGIO) has several interesting candidates in its pipeline. However, the company still faces stiff competition.
Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.
Agios (AGIO) Q1 Loss Wider than Expected; Sales Miss
by Zacks Equity Research
Agios posted wider-than-expected loss in the first quarter of 2018. Revenues came below expectations. Revenues also decreased year-over-year.
Why Earnings Season Could Be Great for Agios (AGIO)
by Zacks Equity Research
Agios (AGIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?
by Zacks Equity Research
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.
Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline
by Zacks Equity Research
The FDA approval for Agios' (AGIO) only marketed drug, Idhifa, augurs well for long-term growth. The company is also well on progress track with its lead candidate, ivosidenib, for R/R AML.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Pharma M&A Active This Week: 4 Potential Buyout Targets
by Indrajit Bandyopadhyay
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Agios Pharmaceuticals Shares Rise on Buyout Speculation
by Zacks Equity Research
Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
by Zacks Equity Research
FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.